Table 4.

Univariate and multivariable survival analyses in relation to serum CA125, HE4, ROMA levels and clinicopathologic prognostic variables for patients with EOC

OSDFSPFS
HR95% CIPHR95% CIPHR95% CIP
Univariate analyses
 CA125 ≥Median vs. <median2.201.09–4.450.0283.571.87–6.81<0.0012.431.24–4.760.010
 HE4 ≥Median vs. <median5.692.55–12.67<0.0014.732.40–9.33<0.0015.802.66–12.64<0.001
 ROMA ≥Median vs. <median4.211.96–9.04<0.0014.762.43–9.31<0.0014.582.16–9.68<0.001
 FIGO stage Late vs. early5.281.81–15.360.0026.662.53–17.5<0.0016.492.18–19.350.001
 Residual tumor ≥0 vs. 04.131.84–9.250.0015.972.92–12.21<0.0015.272.41–11.5<0.001
 Histologic type Serous vs. nonserous2.431.15–5.120.0202.571.40–4.720.0022.501.25–5.010.009
 Presence of ascites Yes vs. no3.991.77–8.970.0015.032.48–10.20<0.0014.702.11–10.45<0.001
 Cytology Positive vs. negative8.481.97–36.470.0047.522.28–24.770.0018.872.07–38.020.003
 Lymph nodal involvement Yes vs. no10.332.22–47.890.0035.672.2–14.58<0.0016.962.19–22.150.001
 Age ≥50 vs. <501.051.02–1.080.0011.031.00–1.050.0161.041.01–1.060.006
Multivariable analysis (adjusted for FIGO stage, residual tumor, and histologic type)
 CA125 ≥Median vs. <median1.400.61–3.210.4241.880.92–3.850.0851.350.64–2.880.433
 HE4 ≥Median vs. <median3.981.35–11.750.0122.461.09–5.560.0302.771.12–6.850.028
 ROMA ≥Median vs. <median3.221.21–8.570.0192.671.25–5.720.0112.761.15–6.590.022